181 filings
Page 2 of 10
6-K
3tvn6buhy04g6u xi
2 Nov 23
NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M
10:56am
FWP
dbp2083
2 Nov 23
Free writing prospectus
12:00am
424B5
lg0til6
1 Nov 23
Prospectus supplement for primary offering
6:50pm
6-K
66kax2chqe
1 Nov 23
NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant
6:36pm
6-K
r5edo6kjmh hz9e8eh
23 Oct 23
Strategic Collaborator-presented Phase 1 Pancreatic Cancer Data
6:00am
6-K
oudss04r
11 Oct 23
Voting Rights and Shares Capital of the Company
5:24pm
6-K
emjym2az
4 Oct 23
Current report (foreign)
4:43pm
6-K
ybnfpfyy
29 Sep 23
Current report (foreign)
4:15pm
6-K
sasqki 1bhj91g
28 Sep 23
NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer
4:15pm
6-K
x2qfa8uc6
26 Sep 23
Current report (foreign)
4:33pm
6-K
hr3xx51kykathbx4wzmn
26 Sep 23
NANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023
4:15pm
6-K
vwe60w1cqs ps
19 Sep 23
Current report (foreign)
4:15pm
6-K
uds0nizn1r f8
13 Sep 23
Voting Rights and Shares Capital of the Company
4:15pm
6-K
1j05w
5 Sep 23
NANOBIOTIX Strengthens Global Development Capabilities With the Appointment of Veteran Industry Leader Dr. Louis Kayitalire as Chief Medical Officer
4:15pm
6-K
njx86ur
31 Aug 23
NANOBIOTIX to Present at the H.C. Wainwright 25th Annual Global Investment Conference
4:15pm
6-K
8uyrrlq4lmd3 lb56
15 Aug 23
Current report (foreign)
4:15pm
6-K
roftj do9
4 Aug 23
NANOBIOTIX to Host Extraordinary General Meeting of Shareholders on September 1st, 2023
4:15pm
6-K
2ck51e5bzmt8mrzlk6
20 Jul 23
Voting Rights and Shares Capital of the Company
4:15pm
6-K
fezwd
19 Jul 23
Current report (foreign)
4:15pm
6-K
ocf1hqw
10 Jul 23
NANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3
6:05am